Document 6423711

James Wm. Forsythe, MD, HMD
Board Certified Medical Oncologist
Board Certified Internal Medicine
Certified in Homeopathy
www.drforsythe.com
[email protected]
Forsythe Immune Therapy (FIT)
Out-Come Based Investigation
300 Patients - 23 Months
From 06/10 - 04/12
Using CST + IPT
1
James Wm Forsythe, MD, HMD
Board Certified Internal Medicine
Board Certified Medical Oncologist
Certified in Homeopathy
I have no potential conflict of interest relationships to my
presentation.
Status of FDA devices used for the material being presented:
NA/Non-Clinical
Status of off-label use of devices, drugs or other materials that
constitute the subject of this presentation: NA/Non-Clinical
2
Original Mission of the
Forsythe Immune Therapy (FIT) Study
• Test efficacy of CST + IPT with the
following:
1. Low-Dose Chemo (fractionated)
2. Poly MVA + FIT alone
3. Super “C” + H2O2
4. Combinations of all the above
5. CST + IPT in all cases
3
FIT 23 Month Report on
300 Stage IV Adult Cancer Patients
Survival Column requirements:
1. Stable Remission for at least one
month
2. All patients counted even if expired
3. Must have measurable parameters (XRays, CT scans, PET scans, MRIs,
USs and tumor markers)
4
5
Earlier Poly-MVA Study
2004-2010 – FIT II
• 225 patients with Stage IV cancers of
multiple origins
• Poly MVA alone
• Poly MVA + Chemotherapy
6 year Overall Survival (OS) rate
of 32%
6
POLY- MVA:
THE PRODUCT
1. A patented palladium lipoic compound
2. MVA: Minerals: molybdenum, rhodium & ruthenium
Vitamins: B1, B2, B12
Amino Acids: formyl-mcthionine, acetylcysteine
3. Palladium (PL) is a rare metal often combined with platinum in
jewelry. M.W. 106 found in nature alloyed with platinum,copper
and nickel. Highly conductive metal.
4. ALA a super antioxidant and detoxifier. It is both water and fat
soluble. It is an effective chelator with heavy metals.
5. Ongoing POLY-MVA study of 225 patients with Stage IV
cancers of multiple origins at four years shows an Overall
Survival (OS) of 32% when used alone or with chemotherapy.
7
Past and Ongoing Clinical
Outcome – Based Cancer Studies
TIME
PRODUCT
Mode of Action
2002-2003
Paw-paw
NSP
Poly-MVA
AMARC
Energetics
2004-Present
Hyper-energizes
Promotes Apoptosis
2005-Present
FIT Study
Combination
therapy
2010- Present
CST + IPT
Chemo-sensitivity
testing with IPT
8
FINDING
THE “TRIGGER” FOR CANCER
Potential Cause(s)
Tests
Heavy Metal
Toxicities
Hair analysis
Blood/Urine
Chemical Toxicities
Blood ELISA
Allergies: food
& inhalants
Blood & Skin
Viral Etiology
HPV, HIV, EBV,
HEP B/C
Immune
Competence
Lymph Subset &
NKC panel
9
Unique Characteristics of
Cancer Cells
Used in Integrative Oncology
• Simple Sugars – malignant cells have increased numbers of
insulin receptors to attract sugar molecules (i.e. PET Scan
basis)
• Acidity – A lower intracellular ph in the biological terrain is
ideal for malignant cell growth – hence use the value of
alkalinization – (i.e. zeolite, cesium or green powders)
• Hypoxia – Malignant cells use anaerobic metabolism primarily
thus the value of various O2 therapies – HBO / H2O2 / Ozone
• Low Voltage – Malignant cells are low energy systems and
produce only 5% ATP of normal cells – thus hyper-energizing
therapy – Poly-MVA
10
Conventional Oncology
Examples of First, Second & Third Line
Chemo Protocols used in Stage IV Cancers
Cancer
Origin
Stage
1st
2nd
3rd
BREAST
IV
Taxane
Xeloda
+/- Avastin +/- Avastin
Navelbine
+/- Avastin
CRC
IV
FOLFOX
FOLFERI
+/- Avastin +/- Avastin
XELODA
+/- Erbitux
H/N
IV
5FU/Carbo
Taxane
Erbitux
+/- MTX
LUNG
IV
Carbo/Taxol
Tarceva
Navelbine
OVARY
IV
Carbo/Taxol
DOXIL
TOPO
PROSTATE
IV
Zoladex
+/- Casodex
KETO/HC
Taxotere
+ Pred
11
12
FIT / POLY–MVA
INVESTIGATION
TUMOR PARAMETERS
1. Physical Exam – tumors in skin, liver, spleen
lymph nodes, etc…
2. X-Rays: tumors detectable in CXR, bone XRays, mammograms, etc…
3. CT Scanning: tumors detectable in brain, chest,
abdomen, pelvis or bones
4. Ultrasounds: breasts, GB., liver, ovaries, spleen,
etc…
5. MRI’s: brain, neck, sinuses, joints, breasts,
muscles, soft tissues, etc…
6. Pet Scans: total body scanning
7. Chemo-sensitivity Testing on whole blood
13
FIT / POLY-MVA + COMBINATION THERAPY
INDIVIDUAL TUMOR MARKERS
1. Bladder - NMP-22, BTA
2. Breast - CEA, CA 27-29, CA-15-3
3. Colorectal – CEA, CA 19-9, 5HIAA (Carcinoids)
4. Esophagus – CEA, CA 19-9
5. Gastric – CEA, CA 19-9
6. Liver – AFP, CEA, & CA19-9
7. Lung – CEA, CA 19-9
8. Lymphomas - ESR, LDH, Beta – 2 Microglobulin
9. Myeloma - B2MG, SPE, LDH
10.Pancreas – CEA, CA 19-9
11.Prostate – PSA, Free PSA
12.Ovary – CA-125
13.Testes – AFP, HCG
14
HISTORICAL CONTROLS
CHEMO-RESISTANT
LITERATURE REVIEW - LONGEVITY
CANCER ORIGIN
Breast
Colorectal
Head / Neck
STAGE IV HISTORICAL
CONTROLS (Chemo-resistant)
on Longevity
6 – 12 months
3 – 6 months
4 – 8 months
Hematological
6 – 8 months
Lung
3 – 6 months
Prostate
6 – 9 months
15
Protocol-FIT
Proprietary Blend
1.
2.
3.
4.
5.
6.
Normal Saline
7. L-Lysine
Magnesium Chloride 8. Zinc
Pyridoxine
9.L-Glutathione
Vitamin B-12
10. Folic Acid
Vitamin C
11. DMSO
B Complex
16
Safety Profile
IV / Oral Poly-MVA / FIT +COMBINATION THERAPY
Investigation
Nausea / Vomiting
0%
Diarrhea (oral only)
<5%
Short of Breath
<5% (40 ml only)
Skin Rash
0%
ABN Liver Tests
0%
Transfusion Reactions
(shakes/chills)
ABN Renal Tests
<5%
Sulfa Allergies (DMSO)
<5%
17
0%
NEW TECHNOLOGY
CHEMO-SENSITIVITY TESTING
• Performed on whole blood
• Four High Tech Labs World-Wide
• Cancer cells harvested from blood
subjected to genetic decoding
• Results include: 18 varieties of chemo drugs, targeted
agents and 36 individual supplements
• Protocol written marrying best drugs with effective
supplements
• Produces blueprint for patient’s specific cancer
• Low-dose fractionated Chemotherapy / IPT treatment
offered to all patients
18
19
Benefits of CST Testing
Goodgene Labs
• Blueprint for patient’s chemotherapy
protocol
• Identify the best hormonal and supplement
therapies
• Identify the best of 12 separate tumors
markers
• Identify the viral etiologies-HPV, HIV, EBV
and HEP B/C
• Access to autologous stem cell RX
• Access to cytokine vaccine RX
20
GOODGENE / VITAMINCHIP CANCER PROGRAMING
TESTTM REPORT
PART VII. RECOMMENDATION (FOR DOCTOR)
A. Based on the result of the present test, following
therapy can be recommended:
1)Chemotherapy and Molecular targeting drug
Capecitabine 850mg/m2 PO bid 2 weeks on and 1 week off
provided with celecoxib and high dose vitamin B6/B12 .
Tykerb 5T daily PO
Bevacizumab (Avastin) in high dose (15mg/kg) once every
3 week
2) Administration of poly-MVA, high dose vitamin C, etc as
complementary alternative therapy.
3) NK/T cell therapy
4) DNA vaccine and dendritic cell targeting markers of
cancer, including EGF receptor, VEGF, etc
5) Administration of chemodrug and tumor suppressor
gene drug (p53, interleukin-24) can be also considered.
21
A Better Life via Goodgene Technology
Goodgene Group
22
Standard 3 week
FIT + IPT Protocol
(06/10-04/12)
•
•
•
•
•
•
Monday - FIT + Poly-MVA IV
Tuesday - IPT + L-Glutathione IV
Wednesday - Super “C” – 60 grams + H2O2 IV
Thursday - IPT + L-Glutathione IV
Friday - FIT + Poly-MVA IV
Refer to other geographically closer IPT
practitioner
23
RGCC TESTING LAB – GENE PROBES
TS
DHFR
TUBULIN
TOPO
SHMT
DPD
IP
p27
p53
DNA
M-TRANS
O6AT
DNAdeam
MPP
LRP
GST
BEGF
PDGF
EGF
TGFb
MMP9
NUC-REDUCT
COX-2
S-lox
SS-r
C-erb2
24
The Greek RGCC Supplement
Recommendations
ARTEMESIA
Poly-MVA
Salvestrol
Ellagic acid
H2O2
Thalid
Uncara tom
L-Meth
Vitamin C
Quercetin
Carctrol
NAC
Vitamin B6
Cox-2
Noni juice
Vitamin B3
Mistletoe
Cytokines
Acetogen
L-carnitine
Ukrain
Carnivora
Cesium Cl
Vitamin E
Vitamin B17
COQ 10
Mitake
SOD
Coll Silver
Essiac tea
Curcumin
Selenium
DIM
Mod cit pec
Green tea
Aloe Vera
C-Statin
IP-6
Melatonin
Alpha IFN
25
RGCC Chemosensitivity Testing
Commonly Recorded Supplements
Quercetin
Poly-MVA
Artemesia
Salvestrol
Vitamin C
Ukrain
C-Statin
DIM
Mistletoe
Curcumin
26
Goodgene Chemosensitivity Testing
Commonly Recorded Supplements
Quercetin
Poly-MVA
Vitamin D3
Vitamin E
Vitamin C
Resveratrol
Beta-Glycam
DIM
IP-6
Curcumin
27
Total Survivors on CST + IPT
300 Patients 23 Months Study
Survivors: 225/300
Percents Survivors = 75%
28
Response Rates at 23 months
300 patients with Stage IV Cancers
Cancer Origin
Total #
% survivors
Appendix
2/2
100%
Bladder
1/2
50%
Breast
47/50
94%
CRC
12/23
52%
HD
2/2
100%
Head/Neck
9/9
100%
Lung
15/27
55%
29
Response Rates at 23 months
300 patients with Stage IV Cancers
Cancer Origin
Total #
% Survivors
Melanomas
4/4
100%
Myeloma
4/5
80%
NHL
7/10
70%
Pancreas
5/9
55%
Prostate
28/28
100%
Thyroid
2/2
100%
30
31
Conclusions:
Conventional
Chemotherapy Results
* Five year Overall
Survival Rate
(OS) Stage IV Cancers
Adjuvant Cytotoxic
Chemotherapy for 22
major adult
malignancies
United States
2.1%
Australia
2.3%
*Reported from the Journal of Clinical
Oncology (2004) 16:549-560
32
Forsythe Immune Therapy (FIT)
Summary
300 Patients over 23 months
•
•
•
•
Integrative Oncology attempts to treat the whole
patient-not just an organ i.e. prostate, lung, etc…
CWC patients undergo a thorough hx and physical
exam and complete review of pathological,
radiological and lab data similar to conventional
oncology.
More than the above CWC studies patients’
emotional health, underlying toxicities, toxic heavy
metals, allergies, chemicals, dental health and
infections.
Electro-dermal testing is preformed to uncover
underlying organ dysfunction.
33
Forsythe Immune Therapy (FIT)
Summary
300 Patients over 23 months (cont.)
• The most important new addition to the FIT program is the
addition of chemo-sensitivity testing - 18 families of
chemotherapy agents along with 38 separate supplements
performed on whole blood genetic decoding.
• The three chemo-sensitivity labs internationally are:
Germany – Biofocus; So. Korea - Goodgene; Greece-Research
Genetic Cancer Centre.
• The 23 month results on 300 patients shows a survivorship
at 75% – aiming for results for 5 years
• The FIT program offers patients a full spectrum menu which is
based on their own choices guided by chemo-sensitivity and
supplement sensitivity testing.
34
Integrative Oncology
Philosophy
“In Stage IV adult cancers of any origin
improvement in quality of life issues is
directly proportional to improvement to
overall response rate. Even stable
disease can be tolerated and
metamorphosed into a chronic livable
condition.”
~James W Forsythe, MD, HMD~
35
Integrative Oncology
Philosophy (continued)
This is true provided that this improvement is not gained at the
expense of toxic chemotherapy or radiation therapy leaving the
patient with many of the following adverse side effects:
• Chemo Brain Syndrome
• Painful Neuropathies
• Cardiomyopathies
• Renal Failure / Platinum toxicities
• Hepatic Failure
• Severe Pancytopenias
• Pulmonary Fibrosis
• Devastating Fatigue, Anorexia and Wasting Syndromes
• Osteoarthritis, myalgias, osteoporosis
• Severe dermatoses
• Death
This study shows that the “cure or kill” approach to advanced
cancer treatment is not the only answer.
36
Cancer Patients’ Bill of Rights
1.
Positive Attitude
6. Limit Certain Tests
2.
Alternate Path
7. Important Knowledge
3.
Stay Alert
8. Be Wary of Media
4.
Remain Positive
9. Refuse Certain Surgeries
5.
Adopt Good Eating Habits
10. Limit Pharmaceuticals
37
Books written, co-written, or single chapters contributing to cancer books
by Dr. Forsythe
Suzanne Somers’ number one best sellers:
KNOCKOUT, Interviews with Doctors who are Curing Cancer
and
Breakthrough, Eight Steps To Wellness
The Ultimate Guide To Natural Health, Quick Reference A-Z Directory of
Natural Remedies for Diseases and Ailments
The Healing Power of Sleep
Sleep and Grow Young
Natural Pain Killers
Emergency Radiation Medical Handbook, The Essential Mandatory Guide
for Citizens and Responders to Nuclear Events
Obaminable Care-A Prescription for Choas
An Alternative Medicine Definitive Guide to Cancer
Alternative Medicine Guide to Women’s Health 2 Series
38
Dr. Forsythe’s New Books
DrForsythe.com or Amazon.com
39